Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,214 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Malignant Neoplasm of Large Intestine Clear all
Completed Phase 1Phase 2 Interventional

Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

NCT00026299
View directory record Official record
Conditions
Colorectal Cancer
Interventions
ZD1839, oxaliplatin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
12
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 22, 2026, 3:57 PM EDT
Terminated Phase 2 Interventional

Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer

NCT00070265
View directory record Official record
Conditions
Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
oxaliplatin, capecitabine, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 22, 2026, 3:57 PM EDT
Not listed Not applicable Interventional

Augmentation of Screening Colonoscopy With Fecal Immunochemical Testing

NCT00892593
View directory record Official record
Conditions
Colon Cancer
Interventions
Fecal Immunochemical Testing
Device
Lead sponsor
Forsyth Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
3
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 22, 2026, 3:57 PM EDT
Completed Phase 3 Interventional

S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed

NCT00002593
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, levamisole hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2005
U.S. locations
57
States / cities
Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 22, 2026, 3:57 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Feasibility and Safety of Single Port Robot in Colorectal Procedures

NCT03700593
View directory record Official record
Conditions
Colon Cancer, Colon Polyp, Rectal Cancer, Diverticulitis, Prolapse, Rectal, Rectal Polyp, Inflammatory Bowel Diseases
Interventions
Single Port Robotic Colorectal Surgery
Device
Lead sponsor
Marks Colorectal Surgical Associates
Other
Eligibility
18 Years to 95 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 22, 2026, 3:57 PM EDT
Withdrawn Phase 1 Interventional

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

NCT04500548
View directory record Official record
Conditions
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Primary Central Nervous System Neoplasm, Xeroderma Pigmentosum
Interventions
Biospecimen Collection, Ipilimumab, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer

NCT00098787
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium, Oxaliplatin
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
110
States / cities
Greenbrae, California • Aurora, Colorado • Boulder, Colorado + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 22, 2026, 3:57 PM EDT
Completed Not applicable Interventional

Survivor Choices for Eating and Drinking - Colorectal Cancer

NCT02965521
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, ColoRectal Cancer
Interventions
Website and text messages
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 22, 2026, 3:57 PM EDT
Completed Phase 4 Interventional Results available

Glucagon Use in Colonoscopies

NCT02078726
View directory record Official record
Conditions
Colon Cancer
Interventions
Glucagon
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 22, 2026, 3:57 PM EDT
Completed Phase 2 Interventional

Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

NCT00002933
View directory record Official record
Conditions
Colorectal Cancer
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 22, 2026, 3:57 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 22, 2026, 3:57 PM EDT
Completed Not applicable Interventional Results available

Effectiveness and Implementation of mPATH-CRC

NCT03843957
View directory record Official record
Conditions
Colorectal Cancer, Cancer, Rectum Cancer, Colon Cancer
Interventions
mPATH-CRC, mPATH-Checkin, "high touch" Implementation strategy, "low touch" Implementation Strategy
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
77,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 22, 2026, 3:57 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

NCT03899792
View directory record Official record
Conditions
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 22, 2026, 3:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients

NCT01344330
View directory record Official record
Conditions
Colon Cancer
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
50 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 22, 2026, 3:57 PM EDT
Recruiting No phase listed Observational

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

NCT04668872
View directory record Official record
Conditions
Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastasis Colon Cancer, Colorectal Cancer
Interventions
Y90 TARE, PET/CT, PET/MRI
Radiation · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 3:57 PM EDT
Completed No phase listed Observational

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT05461430
View directory record Official record
Conditions
Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Travera Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 3:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 3:57 PM EDT
Recruiting Not applicable Interventional

Intravital Microscopy in Human Solid Tumors

NCT03823144
View directory record Official record
Conditions
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Primary Malignant Brain Neoplasm, Metastatic Sarcoma, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Resectable Colorectal Carcinoma, Resectable Liver and Intrahepatic Bile Duct Carcinoma, Resectable Pancreatic Carcinoma, Resectable Sarcoma, Stage IV Colorectal Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Brain Neoplasm, Metastatic Breast Carcinoma, Metastatic Liver Carcinoma, Metastatic Pancreatic Carcinoma, Resectable Brain Neoplasm, Resectable Breast Carcinoma, Resectable Gastric Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 22, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

NCT01187901
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Erlotinib, Sulindac, Placebo A, Placebo B
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 69 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 22, 2026, 3:57 PM EDT
Completed Phase 1 Interventional

Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy

NCT00972036
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
SIR-spheres® (Selective Internal Radiation Therapy)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 22, 2026, 3:57 PM EDT
Completed Phase 1Phase 2 Interventional

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

NCT00333502
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • Farmington, New Mexico
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 22, 2026, 3:57 PM EDT
Not listed Phase 2 Interventional

Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer

NCT00005877
View directory record Official record
Conditions
Colorectal Cancer
Interventions
rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Dublin, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 22, 2026, 3:57 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

NCT00003594
View directory record Official record
Conditions
Colorectal Cancer
Interventions
irinotecan, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
430
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 261 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 22, 2026, 3:57 PM EDT
Completed Phase 1 Interventional

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

NCT01923337
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, alisertib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 22, 2026, 3:57 PM EDT